Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression Omnibus. Issue 6 (28th November 2018)
- Record Type:
- Journal Article
- Title:
- Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression Omnibus. Issue 6 (28th November 2018)
- Main Title:
- Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression Omnibus
- Authors:
- Ren, Xiaojing
Ji, Yuanyuan
Jiang, Xuhua
Qi, Xun - Abstract:
- Abstract : Sialic-acid-binding immunoglobulin-like lectin (siglec) regulates cell death, anti-proliferative effects and mediates a variety of cellular activities. Little was known about the relationship between siglecs and hepatocellular carcinoma (HCC) prognosis. Siglec gene expression between tumor and non-tumor tissues were compared and correlated with overall survival (OS) from HCC patients in GSE14520 microarray expression profile. Siglec-1 to siglec-9 were all down-regulated in tumor tissues compared with those in non-tumor tissues in HCC patients (all P < 0.05). Univariate and multivariate Cox regression analysis revealed that siglec-2 overexpression could predict better OS (HR = 0.883, 95%CI = 0.806–0.966, P = 0.007). Patients with higher siglec-2 levels achieved longer OS months than those with lower siglec-2 levels in the Kaplan–Meier event analysis both in training and validation sets ( P < 0.05). Alpha-fetoprotein (AFP) levels in siglec-2 low expression group were significantly higher than those in siglec-2 high expression group using Chi-square analysis ( P = 0.043). In addition, both logistic regression analysis and ROC curve method showed that siglec-2 down-regulation in tumor tissues was significantly associated with AFP elevation over 300 ng/ml ( P < 0.05). In conclusion, up-regulation of siglec-2 in tumor tissues could predict better OS in HCC patients. Mechanisms of siglec-2 in HCC development need further research.
- Is Part Of:
- Bioscience reports. Volume 38:Issue 6(2018)
- Journal:
- Bioscience reports
- Issue:
- Volume 38:Issue 6(2018)
- Issue Display:
- Volume 38, Issue 6 (2018)
- Year:
- 2018
- Volume:
- 38
- Issue:
- 6
- Issue Sort Value:
- 2018-0038-0006-0000
- Page Start:
- Page End:
- Publication Date:
- 2018-11-28
- Subjects:
- alpha-fetoprotein -- hepatocellular carcinoma -- overall survival -- prognosis -- siglec-2
Molecular biology -- Periodicals
Cytology -- Periodicals
572.8 - Journal URLs:
- http://www.bioscirep.org/ ↗
http://firstsearch.oclc.org ↗ - DOI:
- 10.1042/BSR20181423 ↗
- Languages:
- English
- ISSNs:
- 0144-8463
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2089.611600
British Library HMNTS - ELD Digital store - Ingest File:
- 11656.xml